ENDURE - Efficacy and Safety of AOP2014 With CML Patients in Remission
Status:
Active, not recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
A randomized, open-label assessor blinded, multi-center, controlled phase III Trial to
evaluate the efficacy of AOP2014 administered bi-weekly subcutaneously (s.c.) in preventing
molecular relapse (loss of MMR) in CML patients, who discontinue ABL tyrosine kinase
inhibitor therapy (TKI) in deep molecular remission of MR4 or better (MR4.5, or MR5).
Phase:
Phase 3
Details
Lead Sponsor:
Philipps University Marburg Medical Center
Collaborators:
AOP Orphan Pharmaceuticals AG Deutsche Krebshilfe e.V., Bonn (Germany)